MVD

MVD
МВД России · Public domain · source
Name	MVD

MVD

MVD is a medical condition characterized by structural or functional abnormalities affecting small vessels or microvascular territories, historically discussed across literature involving cardiology, neurology, nephrology, and endocrinology. Accounts of MVD appear in clinical reports from institutions such as Mayo Clinic, Johns Hopkins Hospital, Cleveland Clinic, and research consortia including World Health Organization–affiliated study groups and national registries. Influential investigators and clinician-researchers associated with MVD topics include teams at Harvard Medical School, Stanford University School of Medicine, Imperial College London, and authors publishing in journals like The New England Journal of Medicine, The Lancet, and Journal of the American College of Cardiology.

Definition and Overview

MVD denotes a spectrum of pathology affecting small arteries, arterioles, capillaries, and venules in specific organs; discussions of MVD intersect with findings reported by investigators at European Society of Cardiology, American Heart Association, American College of Cardiology, American Academy of Neurology, and specialty societies. Historical descriptions appear in case series from Guy's Hospital, Royal Brompton Hospital, and classic pathological studies by researchers at John Radcliffe Hospital and Massachusetts General Hospital. Reviews synthesizing MVD concepts are found in articles authored by groups affiliated with University of Oxford, University of Cambridge, and Yale School of Medicine.

Causes and Pathophysiology

Etiologies linked to MVD are often multifactorial and have been explored in cohorts from Framingham Heart Study, Atherosclerosis Risk in Communities Study, and biobanks such as UK Biobank. Common contributors reported by authors at Columbia University Irving Medical Center and University of Pennsylvania include microatheroma, endothelial dysfunction, inflammation, and remodeling described in mechanistic studies at National Institutes of Health laboratories. Systemic disorders implicated in organ-specific microvascular disease have been characterized in cohorts from Johns Hopkins Bloomberg School of Public Health and Mayo Clinic School of Medicine, including associations with autoimmune conditions studied at Cleveland Clinic Foundation and metabolic disorders documented by investigators at Joslin Diabetes Center. Genetic predispositions have been analyzed by consortia involving Broad Institute, Wellcome Trust Sanger Institute, and research groups at Karolinska Institutet. Pathways studied by teams at Max Planck Institute for Heart and Lung Research and Salk Institute include endothelial nitric oxide synthase signaling, oxidative stress cascades, microvascular rarefaction, and perivascular inflammation reported in experimental models from University of California, San Francisco and University of Pittsburgh.

Clinical Presentation and Diagnosis

Clinical manifestations described in case reports from Mount Sinai Hospital, Royal Melbourne Hospital, and tertiary centers such as Toronto General Hospital vary by organ: chest pain syndromes reported in cardiology series from Brigham and Women's Hospital; cognitive impairment and focal deficits described in neurology cohorts at Mayo Clinic and Massachusetts General Hospital; renal dysfunction characterized in nephrology studies at University College London Hospital and St Thomas' Hospital. Diagnostic strategies endorsed by panels from European Society of Cardiology and American Heart Association integrate noninvasive imaging from vendors and centers using modalities developed at GE Healthcare, Siemens Healthineers, and Philips Healthcare alongside invasive testing refined at Cleveland Clinic and Johns Hopkins Hospital. Tests cited in multicenter protocols include perfusion magnetic resonance imaging protocols validated at University of California, Los Angeles, positron emission tomography methods standardized by groups at University of Vienna, coronary flow reserve and microvascular resistance indices introduced in trials coordinated by Duke University School of Medicine, and histopathology criteria derived from autopsy series performed at Cambridge University Hospitals. Diagnostic algorithms appear in guidelines from European Association of Percutaneous Cardiovascular Interventions and task forces convened at American College of Cardiology.

Treatment and Management

Therapeutic approaches reported in randomized trials and registries from Duke Clinical Research Institute, National Heart, Lung, and Blood Institute, and international consortia combine symptomatic therapies, disease-modifying strategies, and organ-targeted interventions. Pharmacologic regimens discussed in publications from Vanderbilt University Medical Center, Stanford Health Care, and University of Michigan include agents affecting endothelial function, antiplatelet therapies studied in trials at Monash University, statins evaluated in meta-analyses by teams at University of Toronto, and vasodilator strategies trialed at Hôpital Européen Georges-Pompidou. Nonpharmacologic management, rehabilitation, and risk-factor modification protocols derive from programs at Karolinska University Hospital, National University Hospital (Singapore), and lifestyle intervention trials coordinated by Harvard T.H. Chan School of Public Health. For refractory cases, invasive procedures and device therapies reported from Cleveland Clinic, Mayo Clinic, and centers of excellence such as Hospital Clínic de Barcelona are considered, with outcomes tracked in registries sponsored by Society for Cardiovascular Angiography and Interventions.

Epidemiology and Prognosis

Epidemiologic data are reported from population studies including Framingham Heart Study, Rotterdam Study, Atherosclerosis Risk in Communities Study, and national databases maintained by Centers for Disease Control and Prevention and National Health Service (England). Prevalence estimates vary across cohorts from Japan Radiological Society and multicenter registries in Europe and North America, with demographic patterns described in analyses performed at University of Sydney and Seoul National University Hospital. Prognosis depends on organ involvement and comorbidities; longitudinal outcomes reported by groups at University of California, San Diego, Johns Hopkins Bloomberg School of Public Health, and Imperial College London document associations with adverse cardiovascular events, cognitive decline, renal progression, and mortality. Risk stratification models have been developed in collaborations involving International Society for Heart and Lung Transplantation and policy bodies such as European Medicines Agency.

Category:Diseases